home · filing · 0001396814-25-000017
8-K filed January 21, 2025, 6:59 PM ET
ticker PCRX
CIK 0001396814
leadership
confidence high
sentiment positive
materiality 0.60
Pacira appoints Brendan Teehan as CCO, Krys Corbett as CBO; adds 785K shares to inducement plan
Pacira BioSciences, Inc.
Brendan Teehan named Chief Commercial Officer effective Jan 21, 2025; previously COO at Acadia Pharmaceuticals.
Krys Corbett appointed Chief Business Officer; most recently led portfolio strategy at Lyell Immunopharma.
Daryl Gaugler transitions from COO to EVP Commercial Operations; compensation and agreement unchanged.
Board adopted amended inducement plan adding 785,000 shares (total 2,310,000) and extending term to Jan 2035.
Company cites '5x30' strategy to grow commercial base and advance pipeline toward innovative biopharma.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2025-01-21
Filed January 21, 2025, 6:59 PM ET
On January 16, 2025, Brendan Teehan was appointed Chief Commercial Officer of Pacira BioSciences, Inc. (the “Company”), effective January 21, 2025.
Role change
Daryl Gaugler
Executive Vice President, Commercial Operations
PCRX ·
Pacira BioSciences, Inc.
Effective 2025-01-16
Filed January 21, 2025, 6:59 PM ET
On January 16, 2025, Daryl Gaugler was named Executive Vice President, Commercial Operations, instead of his former title as Chief Operating Officer.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brendan Teehan was appointed as Chief Commercial Officer at Pacira BioSciences, Inc..
Action appointed
Role Chief Commercial Officer
Exact text from the filing
On January 16, 2025, Brendan Teehan was appointed Chief Commercial Officer of Pacira BioSciences, Inc. (the “Company”), effective January 21, 2025.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Daryl Gaugler was named as Executive Vice President, Commercial Operations at Pacira BioSciences, Inc..
Action named
Role Executive Vice President, Commercial Operations
Exact text from the filing
On January 16, 2025, Daryl Gaugler was named Executive Vice President, Commercial Operations, instead of his former title as Chief Operating Officer.
View on SEC.gov
Source: SEC EDGAR
accession 0001396814-25-000017
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.